Ascendis Pharma A/S (NASDAQ:ASND) Given New $160.00 Price Target at TD Cowen

Ascendis Pharma A/S (NASDAQ:ASND) had its target price lifted by TD Cowen from $157.00 to $160.00 in a research report sent to investors on Monday, Benzinga reports. TD Cowen currently has a buy rating on the biotechnology company’s stock.

A number of other research firms also recently commented on ASND. JPMorgan Chase & Co. dropped their target price on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating on the stock in a report on Wednesday, September 4th. Bank of America upped their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Wells Fargo & Company upped their target price on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Evercore ISI increased their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research note on Tuesday, September 17th. Finally, StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Thursday, September 5th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $195.92.

Ascendis Pharma A/S Trading Up 1.7 %

Shares of ASND stock opened at $129.81 on Monday. Ascendis Pharma A/S has a 52 week low of $85.38 and a 52 week high of $161.00. The company has a market cap of $7.56 billion, a PE ratio of -13.51 and a beta of 0.64. The company’s fifty day simple moving average is $134.90 and its 200-day simple moving average is $134.65.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. Equities research analysts expect that Ascendis Pharma A/S will post -7.2 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in ASND. GAMMA Investing LLC grew its stake in shares of Ascendis Pharma A/S by 52.0% in the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 102 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Ascendis Pharma A/S by 14.3% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 7,034 shares of the biotechnology company’s stock worth $1,063,000 after purchasing an additional 882 shares during the last quarter. Private Ocean LLC acquired a new stake in Ascendis Pharma A/S during the 1st quarter valued at approximately $36,000. Matisse Capital grew its position in shares of Ascendis Pharma A/S by 2.6% during the 1st quarter. Matisse Capital now owns 35,540 shares of the biotechnology company’s stock worth $5,373,000 after buying an additional 905 shares during the period. Finally, BNP Paribas Financial Markets grew its position in shares of Ascendis Pharma A/S by 4,231.4% during the 1st quarter. BNP Paribas Financial Markets now owns 75,540 shares of the biotechnology company’s stock worth $11,419,000 after buying an additional 73,796 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.